CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 996 enrolled
Drug / intervention
MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03652610
NCT03652610Phase 2Completed
CompareCT.gov

Immunogenicity, Reactogenicity and Safety of Two Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) in Healthy Adults 18 to 40 Years of Age

GlaxoSmithKline·interventional·Posted Aug 29, 2018·Updated Feb 9, 2021

In Brief

A Phase 2 clinical trial evaluating MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A) and Licensed GSK MenACWY vaccine (Menveo) for Infections, Meningococcal. Completed, enrolled 996 participants across 30 sites in 5 countries.

Detailed Summary

MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more than 60 countries. The purpose of this study is to compare the immunogenicity of the currently licensed MenACWY vaccine with the investigational MenACWY liquid vaccine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Meningococcal
CountriesAustralia, Belgium, Canada, Germany, Italy
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 29, 2018
Enrollment StartSep 7, 2018
Primary CompletionJan 17, 2019
Study CompletionJun 11, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.8 years ago

Interventions

MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)biological

Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm

Licensed GSK MenACWY vaccine (Menveo)biological

Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm